{"entity":{"id":"nct06745882","kind":"trial","name":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","aka":[],"tldr":"A phase 2 trial of cisplatin, carboplatin, pemetrexed, pembrolizumab and other drugs in lung cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.","summary":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC is a phase 2, interventional study registered as NCT06745882 by H. Lee Moffitt Cancer Center and Research Institute, with a registry enrolment figure of 318 participants, started 2025-06-13 and due to reach its primary completion in 2030-01. Interventions recorded: Cisplatin; Carboplatin; Pemetrexed; Pembrolizumab; Abraxane; Paclitaxel. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Cohort 1: Real World Overall Survival (rwOS); Cohort 2 Arm A: Progression Free Survival (PFS); Cohort 2 Arm B: Progression Free Survival (PFS). Lung eligibility wording from the registry: \"* Have histologically or cytologically confirmed, advanced/metastatic NSCLC\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06745882","url":"https://clinicaltrials.gov/study/NCT06745882"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["cisplatin","carboplatin","pemetrexed","pembrolizumab","nab-paclitaxel","paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06745882","phase":"2","setting":"Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","enrolled":318,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06745882/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}